When type 2 diabetes coexists with atrial fibrillation in Middle Eastern patients: Clinical profiles and utilization of oral anticoagulant agents

Abstract Funding Acknowledgements Type of funding sources: None. OnBehalf The Jordan Atrial Fibrillation (JoFib) Study Background. Studies from different regions in the world have shown that patients with atrial fibrillation (AF) who have type 2 diabetes mellitus (T2D) have unfavorable baseline clinical profile, higher prevalence of comorbidities and higher risk scores compared with those who do not have T2D. It is largely unknown if this applies to Middle Eastern (ME) patients. Purpose. To evaluate baseline clinical features, prevalence of comorbid diseases, CHA2DS2-VASc scores in AF patients with T2D, and the utilization of oral anticoagulant agents (OACs) compared with those who do not have T2D in a large ME cohort. Methods. Of 2163 AF patients enrolled in the Jordan AF study (May 2019 - January 2021), 953 (44.1%) had T2D and 1210 (55.9%) did not have T2D. Nonvalvular AF (NVAF) was diagnosed in 94% and 89% of both groups, respectively. Compared with AF patients who did not have T2D, those with T2D were older (mean age 70.3 ± 9.7 years vs. 65.9 ± 15.1 years, p